Earth Science Tech (ETST) Net Income towards Common Stockholders (2011 - 2026)
Earth Science Tech's (ETST) quarterly Net Income towards Common Stockholders came in at $715697.0 in Q2 2026, up 56.71% on a YoY basis from $456714.0 in Q2 2025, and down 44.43% quarter-over-quarter from $1.3 million in Q1 2026.
Powered by 
Analysis
Earth Science Tech (ETST) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Earth Science Tech (ETST) has reported Net Income towards Common Stockholders for 15 consecutive years, with $715697.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 56.71% year-over-year to $715697.0; the trailing twelve-month figure through Jun 2026 stood at $3.9 million (up 46.54% YoY), and the FY2026 full-year result was $3.6 million, up 10.67% from the prior year.
- Net Income towards Common Stockholders fell to $715697.0 in Q2 2026 per ETST's latest filing, from $1.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.3 million in Q1 2026 and bottomed at -$235509.0 in Q1 2023.
- Historically, Net Income towards Common Stockholders has averaged $446551.9 across 5 years, with a median of $336952.5 in 2023.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders sank 667.61% in 2023, then surged 3123.53% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at $98464.0 in 2022, then jumped by 128.96% to $225443.0 in 2023, then slipped by 8.44% to $206411.0 in 2024, then jumped by 341.05% to $910368.0 in 2025, then retreated by 21.38% to $715697.0 in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $715697.0, $1.3 million, and $910368.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.61 Bn | 38.95 Bn | 2.15 Bn | -576.00 Mn |
| 2 | Viatris | 19.18 Bn | 18.30 Bn | 1.46 Bn | -118.80 Mn |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | 46.85 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | 69.61 Mn |
| 5 | Bausch Health Companies | 2.36 Bn | 518.87 Mn | 2.10 Bn | 260.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -66.70 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 24.70 Mn |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | 30.35 Mn |
| 9 | Fennec Pharmaceuticals | 405.56 Mn | 364.31 Mn | 17.15 Mn | 1.97 Mn |
| 10 | Earth Science Tech | 25.88 Mn | 23.09 Mn | 6.28 Mn | 715,697.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 715,697.00 |
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 910,368.00 |
| Sep 30, 2025 | 945,897.00 |
| Jun 30, 2025 | 456,714.00 |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 206,411.00 |
| Sep 30, 2024 | 798,368.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 229,324.00 |
| Dec 31, 2023 | 225,443.00 |
| Sep 30, 2023 | 444,581.00 |
| Jun 30, 2023 | -35,596.00 |
| Mar 31, 2023 | -235,509.00 |
| Dec 31, 2022 | 98,464.00 |
| Sep 30, 2022 | -73,678.00 |
| Jun 30, 2022 | -154,682.00 |
| Mar 31, 2022 | -30,681.00 |
| Dec 31, 2021 | -115,048.00 |
| Sep 30, 2021 | 3.34 Mn |